Frazier Healthcare Partners — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
.png)
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersRA CapitalSamsara BioCapital
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersSanofi VenturesSV Health InvestorsDementia Discovery FundTPG
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.